<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39319193</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1177-8881</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>Drug design, development and therapy</Title><ISOAbbreviation>Drug Des Devel Ther</ISOAbbreviation></Journal><ArticleTitle>Cytokine Storm-Induced Thyroid Dysfunction in COVID-19: Insights into Pathogenesis and Therapeutic Approaches.</ArticleTitle><Pagination><StartPage>4215</StartPage><EndPage>4240</EndPage><MedlinePgn>4215-4240</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2147/DDDT.S475005</ELocationID><Abstract><AbstractText>Angiotensin-converting enzyme 2 receptors (ACE2R) are requisite to enter the host cells for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). ACE2R is constitutive and functions as a type I transmembrane metallo-carboxypeptidase in the renin-angiotensin system (RAS). On thyroid follicular cells, ACE2R allows SARS-CoV-2 to invade the thyroid gland, impose cytopathic effects and produce endocrine abnormalities, including stiff back, neck pain, muscle ache, lethargy, and enlarged, inflamed thyroid gland in COVID-19 patients. Further damage is perpetuated by the sudden bursts of pro-inflammatory cytokines, which is suggestive of a life-threatening syndrome known as a "cytokine storm". IL-1β, IL-6, IFN-γ, and TNF-α are identified as the key orchestrators of the cytokine storm. These inflammatory mediators upregulate transcriptional turnover of nuclear factor-kappa B (NF-κB), Janus kinase/signal transducer and activator of transcription (JAK/STAT), and mitogen-activated protein kinase (MAPK), paving the pathway for cytokine storm-induced thyroid dysfunctions including euthyroid sick syndrome, autoimmune thyroid diseases, and thyrotoxicosis in COVID-19 patients. Targeted therapies with corticosteroids (dexamethasone), JAK inhibitor (baricitinib), nucleotide analogue (remdesivir) and N-acetyl-cysteine have demonstrated effectiveness in terms of attenuating the severity and frequency of cytokine storm-induced thyroid dysfunctions, morbidity and mortality in severe COVID-19 patients. Here, we review the pathogenesis of cytokine storms and the mechanisms and pathways that establish the connection between thyroid disorder and COVID-19. Moreover, cross-talk interactions of signalling pathways and therapeutic strategies to address COVID-19-associated thyroid diseases are also discussed herein.</AbstractText><CopyrightInformation>© 2024 Attiq et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Attiq</LastName><ForeName>Ali</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9430-0255</Identifier><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afzal</LastName><ForeName>Sheryar</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8387-7550</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wahab</LastName><ForeName>Habibah A</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmad</LastName><ForeName>Waqas</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>School of Pharmaceutical Sciences, Universiti Sains Malaysia, Gelugor, Penang, 11800, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kandeel</LastName><ForeName>Mahmoud</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3668-5147</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, Faculty of Veterinary Medicine, Kafrelsheikh University, Kafrel Sheikh, 6860404, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Almofti</LastName><ForeName>Yassir A</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biochemistry, Molecular Biology and Bioinformatics, College of Veterinary Medicine, University of Bahri, Khartoum, 12217, Sudan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alameen</LastName><ForeName>Ahmed O</ForeName><Initials>AO</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, College of Veterinary Medicine, King Faisal University, Al Ahsa, 31982, Saudi Arabia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Veterinary Medicine, University of Khartoum, Shambat, 13314, Sudan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yuan Seng</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0001-5574-8049</Identifier><AffiliationInfo><Affiliation>Sunway Microbiome Centre, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, 47500, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Sciences, School of Medical and Life Sciences, Sunway University, Subang Jaya, Selangor, 47500, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Des Devel Ther</MedlineTA><NlmUniqueID>101475745</NlmUniqueID><ISSNLinking>1177-8881</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.17.23</RegistryNumber><NameOfSubstance UI="D000085962">Angiotensin-Converting Enzyme 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000080424" MajorTopicYN="Y">Cytokine Release Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000085962" MajorTopicYN="N">Angiotensin-Converting Enzyme 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013961" MajorTopicYN="N">Thyroid Gland</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">cross talks</Keyword><Keyword MajorTopicYN="N">cytokine storm</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">signalling pathways</Keyword><Keyword MajorTopicYN="N">thyroid disorders</Keyword></KeywordList><CoiStatement>The authors report no conflict of interest for the present paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319193</ArticleId><ArticleId IdType="pmc">PMC11421457</ArticleId><ArticleId IdType="doi">10.2147/DDDT.S475005</ArticleId><ArticleId IdType="pii">475005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta A, Madhavan MV, Sehgal K, et al. Extrapulmonary manifestations of COVID-19. Nat Med. 2020;26(7):1017–1032. doi:10.1038/s41591-020-0968-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0968-3</ArticleId><ArticleId IdType="pubmed">32651579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee I-C, Huo T-I, Huang Y-H. Gastrointestinal and liver manifestations in patients with COVID-19. J Chin Med Assoc. 2020;83(6):521–523. doi:10.1097/JCMA.0000000000000319</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JCMA.0000000000000319</ArticleId><ArticleId IdType="pmc">PMC7176263</ArticleId><ArticleId IdType="pubmed">32243269</ArticleId></ArticleIdList></Reference><Reference><Citation>Li M-Y, Li L, Zhang Y, Wang X-S. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Diseases Poverty. 2020;9(02):23–29. doi:10.1186/s40249-020-00662-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40249-020-00662-x</ArticleId><ArticleId IdType="pmc">PMC7186534</ArticleId><ArticleId IdType="pubmed">32345362</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444–1448. doi:10.1126/science.abb2762</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb2762</ArticleId><ArticleId IdType="pmc">PMC7164635</ArticleId><ArticleId IdType="pubmed">32132184</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao P, Praissman JL, Grant OC, et al. Virus-receptor interactions of glycosylated SARS-CoV-2 spike and human ACE2 receptor. Cell Host Microbe. 2020;28(4):586–601.e586. doi:10.1016/j.chom.2020.08.004</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7443692</ArticleId><ArticleId IdType="pubmed">32841605</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattar SAM, Koh SJQ, Rama Chandran S, Cherng BPZ. Subacute thyroiditis associated with COVID-19. BMJ Case Rep. 2020;13(8):e237336. doi:10.1136/bcr-2020-237336</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-237336</ArticleId><ArticleId IdType="pmc">PMC7449350</ArticleId><ArticleId IdType="pubmed">32843467</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohrabpour S, Heidari F, Karimi E, Ansari R, Tajdini A, Heidari F. Subacute thyroiditis in COVID-19 patients. Europ Thyr J. 2021;9(6):321–323. doi:10.1159/000511707</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511707</ArticleId><ArticleId IdType="pmc">PMC7705932</ArticleId><ArticleId IdType="pubmed">33708633</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancatella A, Viola N, Santini F, Latrofa F. COVID-induced thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab. 2023;37(2):101742. doi:10.1016/j.beem.2023.101742</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101742</ArticleId><ArticleId IdType="pubmed">36813660</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DT, Lee CH, Chow WS, et al. Insights from prospective follow-up of thyroid function and autoimmunity among covid-19 survivors. J Endoc Soc. 2021;5(Supplement_1):A840–A841. doi:10.1210/jendso/bvab048.1715</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jendso/bvab048.1715</ArticleId><ArticleId IdType="pmc">PMC8258341</ArticleId><ArticleId IdType="pubmed">34107601</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Su X, Ding Y, et al. Thyroid function abnormalities in COVID-19 patients. Front Endocrinol. 2021;11:623792. doi:10.3389/fendo.2020.623792</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.623792</ArticleId><ArticleId IdType="pmc">PMC7933556</ArticleId><ArticleId IdType="pubmed">33679608</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Lin F, Tu W, et al. Thyroid dysfunction may be associated with poor outcomes in patients with COVID-19. Molecul Cell Endocrinol. 2021;521:111097. doi:10.1016/j.mce.2020.111097</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2020.111097</ArticleId><ArticleId IdType="pmc">PMC7709789</ArticleId><ArticleId IdType="pubmed">33278491</ArticleId></ArticleIdList></Reference><Reference><Citation>Brancatella A, Ricci D, Viola N, Sgrò D, Santini F, Latrofa F. Subacute thyroiditis after Sars-COV-2 infection. J Clin Endocrinol Metab. 2020;105(7):2367–2370. doi:10.1210/clinem/dgaa276</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa276</ArticleId><ArticleId IdType="pmc">PMC7314004</ArticleId><ArticleId IdType="pubmed">32436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovanella L, Ruggeri RM, Ovčariček PP, Campenni A, Treglia G, Deandreis D. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl Imaging. 2021;9(3):233–240. doi:10.1007/s40336-021-00419-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40336-021-00419-y</ArticleId><ArticleId IdType="pmc">PMC7950424</ArticleId><ArticleId IdType="pubmed">33728279</ArticleId></ArticleIdList></Reference><Reference><Citation>Scappaticcio L, Pitoia F, Esposito K, Piccardo A, Trimboli P. Impact of COVID-19 on the thyroid gland: an update. Rev Endocr Metab Disord. 2021;22(4):803–815. doi:10.1007/s11154-020-09615-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11154-020-09615-z</ArticleId><ArticleId IdType="pmc">PMC7688298</ArticleId><ArticleId IdType="pubmed">33241508</ArticleId></ArticleIdList></Reference><Reference><Citation>Aslani M, Mortazavi-Jahromi SS, Mirshafiey A. Cytokine storm in the pathophysiology of COVID-19: possible functional disturbances of miRNAs. Int Immunopharmacol. 2021;101:108172. doi:10.1016/j.intimp.2021.108172</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108172</ArticleId><ArticleId IdType="pmc">PMC8452524</ArticleId><ArticleId IdType="pubmed">34601331</ArticleId></ArticleIdList></Reference><Reference><Citation>Speer G, Somogyi P. Thyroid complications of SARS and coronavirus disease 2019 (COVID-19). Endocr J. 2021;68(2):129–136. doi:10.1507/endocrj.EJ20-0443</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.EJ20-0443</ArticleId><ArticleId IdType="pubmed">33473054</ArticleId></ArticleIdList></Reference><Reference><Citation>Feghali K, Atallah J, Norman C. Manifestations of thyroid disease post COVID-19 illness: report of Hashimoto thyroiditis, Graves’ disease, and subacute thyroiditis. J Clin Translat Endocrinol. 2021;22:100094. doi:10.1016/j.jecr.2021.100094</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jecr.2021.100094</ArticleId><ArticleId IdType="pmc">PMC8387132</ArticleId><ArticleId IdType="pubmed">34462717</ArticleId></ArticleIdList></Reference><Reference><Citation>Clausen CL, Rasmussen ÅK, Johannsen TH, et al. Thyroid function in COVID-19 and the association with cytokine levels and mortality. Endocr Connections. 2021;10(10):1234–1242. doi:10.1530/EC-21-0301</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EC-21-0301</ArticleId><ArticleId IdType="pmc">PMC8494417</ArticleId><ArticleId IdType="pubmed">34468398</ArticleId></ArticleIdList></Reference><Reference><Citation>Lania A, Sandri MT, Cellini M, Mirani M, Lavezzi E, Mazziotti G. Thyrotoxicosis in patients with COVID-19: the THYRCOV study. Europ J Endocrinol. 2020;183(4):381–387. doi:10.1530/EJE-20-0335</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/EJE-20-0335</ArticleId><ArticleId IdType="pmc">PMC9494315</ArticleId><ArticleId IdType="pubmed">32698147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashrafi S, Hatami H, Bidhendi-Yarandi R, Panahi MH. The prevalence of thyroid disorders in COVID-19 patients: a systematic review and meta-analysis. BMC Endocr Disord. 2024;24(1):5. doi:10.1186/s12902-023-01534-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-023-01534-9</ArticleId><ArticleId IdType="pmc">PMC10759498</ArticleId><ArticleId IdType="pubmed">38166835</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera EC, Cisneros TA, Fuentes MSD. Subacute Thyroiditis Associated with COVID-19; 2021.</Citation></Reference><Reference><Citation>Bellastella G, Maiorino M, Esposito K. Endocrine complications of COVID-19: what happens to the thyroid and adrenal glands? J Endocrinol Invest. 2020;43:1169–1170. doi:10.1007/s40618-020-01311-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01311-8</ArticleId><ArticleId IdType="pmc">PMC7265876</ArticleId><ArticleId IdType="pubmed">32488724</ArticleId></ArticleIdList></Reference><Reference><Citation>Damara FA, Muchamad GR, Ikhsani R, Syafiyah AH, Bashari MH, Bashari MH. Thyroid disease and hypothyroidism are associated with poor COVID-19 outcomes: a systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2021;15(6):102312. doi:10.1016/j.dsx.2021.102312</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2021.102312</ArticleId><ArticleId IdType="pmc">PMC8530797</ArticleId><ArticleId IdType="pubmed">34731819</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatri A, Charlap E, Kim A. Subacute thyroiditis from COVID-19 infection: a case report and review of literature. Europ Thyr J. 2021;9(6):324–328. doi:10.1159/000511872</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000511872</ArticleId><ArticleId IdType="pmc">PMC7705942</ArticleId><ArticleId IdType="pubmed">33708634</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Gerwen M, Alsen M, Little C, et al. Outcomes of patients with hypothyroidism and COVID-19: a retrospective cohort study. Front Endocrinol. 2020;11:565. doi:10.3389/fendo.2020.00565</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.00565</ArticleId><ArticleId IdType="pmc">PMC7461836</ArticleId><ArticleId IdType="pubmed">33013686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti CL, Cazarin J, Hecht F, et al. COVID-19 and thyroid function: what do we know so far? Front Endocrinol. 2022;13:1041676. doi:10.3389/fendo.2022.1041676</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.1041676</ArticleId><ArticleId IdType="pmc">PMC9806267</ArticleId><ArticleId IdType="pubmed">36601011</ArticleId></ArticleIdList></Reference><Reference><Citation>Qutob RA, Alhusaini BA, Alzmamy SA, et al. Knowledge and awareness about risk factors, clinical manifestations, and prevention of thyroid disorders in the era of COVID-19 and their association with socioeconomic status among the general population in Riyadh, Saudi Arabia. Cureus. 2023;15(11):e48878. doi:10.7759/cureus.48878</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.48878</ArticleId><ArticleId IdType="pmc">PMC10724758</ArticleId><ArticleId IdType="pubmed">38106726</ArticleId></ArticleIdList></Reference><Reference><Citation>Şendur SN, Oğuz SH, Ünlütürk U. COVID-19 vaccination and thyroiditis. Best Pract Res Clin Endocrinol Metab. 2023;37(4):101759. doi:10.1016/j.beem.2023.101759</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2023.101759</ArticleId><ArticleId IdType="pmc">PMC9981269</ArticleId><ArticleId IdType="pubmed">36933997</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosch BJ, Van der Zee R, De Haan CA, Rottier PJ. The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex. J Virol. 2003;77(16):8801–8811. doi:10.1128/JVI.77.16.8801-8811.2003</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.77.16.8801-8811.2003</ArticleId><ArticleId IdType="pmc">PMC167208</ArticleId><ArticleId IdType="pubmed">12885899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021;19(3):141–154. doi:10.1038/s41579-020-00459-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-020-00459-7</ArticleId><ArticleId IdType="pmc">PMC7537588</ArticleId><ArticleId IdType="pubmed">33024307</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: a review. Clin Immunol. 2020;215:108427. doi:10.1016/j.clim.2020.108427</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108427</ArticleId><ArticleId IdType="pmc">PMC7169933</ArticleId><ArticleId IdType="pubmed">32325252</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Liu Q, Guo D. Emerging coronaviruses: genome structure, replication, and pathogenesis. J Med Virol. 2020;92(4):418–423. doi:10.1002/jmv.25681</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25681</ArticleId><ArticleId IdType="pmc">PMC7167049</ArticleId><ArticleId IdType="pubmed">31967327</ArticleId></ArticleIdList></Reference><Reference><Citation>Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Coronaviruses. 2015;2015:1–23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4369385</ArticleId><ArticleId IdType="pubmed">25720466</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature. 2020;581(7807):215–220. doi:10.1038/s41586-020-2180-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2180-5</ArticleId><ArticleId IdType="pubmed">32225176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARS-CoV-2. Proc Natl Acad Sci. 2020;117(21):11727–11734. doi:10.1073/pnas.2003138117</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2003138117</ArticleId><ArticleId IdType="pmc">PMC7260975</ArticleId><ArticleId IdType="pubmed">32376634</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungnak W, Huang N, Bécavin C, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat Med. 2020;26(5):681–687. doi:10.1038/s41591-020-0868-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-0868-6</ArticleId><ArticleId IdType="pmc">PMC8637938</ArticleId><ArticleId IdType="pubmed">32327758</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhama K, Khan S, Tiwari R, et al. Coronavirus disease 2019–COVID-19. Clin Microbiol Rev. 2020;33(4):e00028–00020. doi:10.1128/CMR.00028-20</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00028-20</ArticleId><ArticleId IdType="pmc">PMC7405836</ArticleId><ArticleId IdType="pubmed">32580969</ArticleId></ArticleIdList></Reference><Reference><Citation>Samudrala PK, Kumar P, Choudhary K, et al. Virology, pathogenesis, diagnosis and in-line treatment of COVID-19. Eur J Pharmacol. 2020;883:173375. doi:10.1016/j.ejphar.2020.173375</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2020.173375</ArticleId><ArticleId IdType="pmc">PMC7366121</ArticleId><ArticleId IdType="pubmed">32682788</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi:10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoops K, Kikkert M, SHvd W, et al. SARS-coronavirus replication is supported by a reticulovesicular network of modified endoplasmic reticulum. PLoS Biol. 2008;6(9):e226. doi:10.1371/journal.pbio.0060226</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.0060226</ArticleId><ArticleId IdType="pmc">PMC2535663</ArticleId><ArticleId IdType="pubmed">18798692</ArticleId></ArticleIdList></Reference><Reference><Citation>Chams N, Chams S, Badran R, et al. COVID-19: a multidisciplinary review. Front Public Health. 2020;8:383. doi:10.3389/fpubh.2020.00383</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2020.00383</ArticleId><ArticleId IdType="pmc">PMC7403483</ArticleId><ArticleId IdType="pubmed">32850602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury. Nat Med. 2005;11(8):875–879. doi:10.1038/nm1267</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1267</ArticleId><ArticleId IdType="pmc">PMC7095783</ArticleId><ArticleId IdType="pubmed">16007097</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116. doi:10.1038/nature03712</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature03712</ArticleId><ArticleId IdType="pmc">PMC7094998</ArticleId><ArticleId IdType="pubmed">16001071</ArticleId></ArticleIdList></Reference><Reference><Citation>Attiq A, Yao LJ, Afzal S, Khan MA. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. Int Immunopharmacol. 2021;101:108255. doi:10.1016/j.intimp.2021.108255</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108255</ArticleId><ArticleId IdType="pmc">PMC8516728</ArticleId><ArticleId IdType="pubmed">34688149</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng KI, Feng G, Liu WY, Targher G, Byrne CD, Zheng MH. Extrapulmonary complications of COVID‐19: a multisystem disease? J Med Virol. 2021;93(1):323–335. doi:10.1002/jmv.26294</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26294</ArticleId><ArticleId IdType="pmc">PMC7405144</ArticleId><ArticleId IdType="pubmed">32648973</ArticleId></ArticleIdList></Reference><Reference><Citation>Mateu-Salat M, Urgell E, Chico A. SARS-COV-2 as a trigger for autoimmune disease: report of two cases of Graves’ disease after COVID-19. J Endocrinol Invest. 2020;43(10):1527–1528. doi:10.1007/s40618-020-01366-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01366-7</ArticleId><ArticleId IdType="pmc">PMC7368923</ArticleId><ArticleId IdType="pubmed">32686042</ArticleId></ArticleIdList></Reference><Reference><Citation>Caron P Thyroid disorders and SARS-CoV-2 infection: from pathophysiological mechanism to patient management. Paper presented at: Annales D’endocrinologie; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498405</ArticleId><ArticleId IdType="pubmed">32950466</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. doi:10.1016/j.jpha.2020.03.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpha.2020.03.001</ArticleId><ArticleId IdType="pmc">PMC7104082</ArticleId><ArticleId IdType="pubmed">32282863</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Gong E, Zhang B, et al. Multiple organ infection and the pathogenesis of SARS. J Exp Med. 2005;202(3):415–424. doi:10.1084/jem.20050828</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20050828</ArticleId><ArticleId IdType="pmc">PMC2213088</ArticleId><ArticleId IdType="pubmed">16043521</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L, Sun S, Zhang J, et al. Endocrine cells of the adenohypophysis in severe acute respiratory syndrome (SARS). Biochem Cell Biol. 2010;88(4):723–730. doi:10.1139/O10-022</Citation><ArticleIdList><ArticleId IdType="doi">10.1139/O10-022</ArticleId><ArticleId IdType="pubmed">20651845</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen M, Zhou W, Xu W. Thyroid function analysis in 50 patients with COVID-19: a retrospective study. Thyroid. 2021;31(1):8–11. doi:10.1089/thy.2020.0363</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2020.0363</ArticleId><ArticleId IdType="pubmed">32600165</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarante-Mendes GP, Adjemian S, Branco LM, Zanetti LC, Weinlich R, Bortoluci KR. Pattern recognition receptors and the host cell death molecular machinery. Front Immunol. 2018;9:2379. doi:10.3389/fimmu.2018.02379</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.02379</ArticleId><ArticleId IdType="pmc">PMC6232773</ArticleId><ArticleId IdType="pubmed">30459758</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D, Wu M, Bi Z. Pattern recognition receptors in health and diseases. Signal Transduct Targ Ther. 2021;6(1):1–24. doi:10.1038/s41392-020-00451-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00451-w</ArticleId><ArticleId IdType="pmc">PMC8333067</ArticleId><ArticleId IdType="pubmed">34344870</ArticleId></ArticleIdList></Reference><Reference><Citation>He S, He J, Chen J, Chen F, Ou S. Research advancement of innate immunity and pattern recognition receptors. ChinJ Animal Nutr. 2017;29(11):3844–3851.</Citation></Reference><Reference><Citation>Onomoto K, Onoguchi K, Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: interaction between host and viral factors. Cell Mol Immunol. 2021;18(3):539–555. doi:10.1038/s41423-020-00602-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00602-7</ArticleId><ArticleId IdType="pmc">PMC7812568</ArticleId><ArticleId IdType="pubmed">33462384</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoneyama M, Onomoto K, Jogi M, Akaboshi T, Fujita T. Viral RNA detection by RIG-I-like receptors. Curr Opin Immunol. 2015;32:48–53. doi:10.1016/j.coi.2014.12.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coi.2014.12.012</ArticleId><ArticleId IdType="pubmed">25594890</ArticleId></ArticleIdList></Reference><Reference><Citation>Medzhitov R, Preston-Hurlburt P, Janeway CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature. 1997;388(6640):394–397. doi:10.1038/41131</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/41131</ArticleId><ArticleId IdType="pubmed">9237759</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V. Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets. Int Immunopharmacol. 2020;89:107087. doi:10.1016/j.intimp.2020.107087</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107087</ArticleId><ArticleId IdType="pmc">PMC7550173</ArticleId><ArticleId IdType="pubmed">33075714</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuliani C, Bucci I, Napolitano G. The role of the transcription factor nuclear factor-kappa B in thyroid autoimmunity and cancer. Front Endocrinol. 2018;9:471. doi:10.3389/fendo.2018.00471</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2018.00471</ArticleId><ArticleId IdType="pmc">PMC6110821</ArticleId><ArticleId IdType="pubmed">30186235</ArticleId></ArticleIdList></Reference><Reference><Citation>Harii N, Lewis CJ, Vasko V, et al. Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto’s autoimmune thyroiditis. Mol Endocrinol. 2005;19(5):1231–1250. doi:10.1210/me.2004-0100</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2004-0100</ArticleId><ArticleId IdType="pubmed">15661832</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari SM, Fallahi P, Elia G, et al. Thyroid autoimmune disorders and cancer. Paper presented at: Seminars in cancer biology 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">31158464</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao LJ, Jalil J, Attiq A, Hui CC, Zakaria NA. The medicinal uses, toxicities and anti-inflammatory activity of Polyalthia species (Annonaceae). J Ethnopharmacol. 2019;229:303–325. doi:10.1016/j.jep.2018.10.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2018.10.001</ArticleId><ArticleId IdType="pubmed">30316887</ArticleId></ArticleIdList></Reference><Reference><Citation>Jalil J, Attiq A, Hui CC, Yao LJ, Zakaria NA. Modulation of inflammatory pathways, medicinal uses and toxicities of Uvaria species: potential role in the prevention and treatment of inflammation. Inflammopharmacology. 2020;28(5):1195–1218. doi:10.1007/s10787-020-00734-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00734-2</ArticleId><ArticleId IdType="pubmed">32617790</ArticleId></ArticleIdList></Reference><Reference><Citation>Attiq A, Jalil J, Husain K. Annonaceae: breaking the wall of inflammation. Front Pharmacol. 2017;8:752. doi:10.3389/fphar.2017.00752</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2017.00752</ArticleId><ArticleId IdType="pmc">PMC5654839</ArticleId><ArticleId IdType="pubmed">29104539</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariharan A, Hakeem AR, Radhakrishnan S, Reddy MS, Rela M. The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients. Inflammopharmacology. 2021;29(1):91–100. doi:10.1007/s10787-020-00773-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00773-9</ArticleId><ArticleId IdType="pmc">PMC7648206</ArticleId><ArticleId IdType="pubmed">33159646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwakkel J, Wiersinga WM, Boelen A. Differential involvement of nuclear factor-κB and activator protein-1 pathways in the interleukin-1β-mediated decrease of deiodinase type 1 and thyroid hormone receptor β1 mRNA. J Endocrinol. 2006;189(1):37–44. doi:10.1677/joe.1.06354</Citation><ArticleIdList><ArticleId IdType="doi">10.1677/joe.1.06354</ArticleId><ArticleId IdType="pubmed">16614379</ArticleId></ArticleIdList></Reference><Reference><Citation>Castro G, Liu X, Ngo K, et al. RORγt and RORα signature genes in human Th17 cells. PLoS One. 2017;12(8):e0181868. doi:10.1371/journal.pone.0181868</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0181868</ArticleId><ArticleId IdType="pmc">PMC5538713</ArticleId><ArticleId IdType="pubmed">28763457</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou W, Kang HS, Kim BS. Th17 cells enhance viral persistence and inhibit T cell cytotoxicity in a model of chronic virus infection. J Exp Med. 2009;206(2):313–328. doi:10.1084/jem.20082030</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20082030</ArticleId><ArticleId IdType="pmc">PMC2646583</ArticleId><ArticleId IdType="pubmed">19204109</ArticleId></ArticleIdList></Reference><Reference><Citation>Josefowicz SZ, Lu L-F, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol. 2012;30:531. doi:10.1146/annurev.immunol.25.022106.141623</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.25.022106.141623</ArticleId><ArticleId IdType="pmc">PMC6066374</ArticleId><ArticleId IdType="pubmed">22224781</ArticleId></ArticleIdList></Reference><Reference><Citation>Attiq A, Afzal S. Trinity of inflammation, innate immune cells and cross-talk of signalling pathways in tumour microenvironment. Front Pharmacol. 2023;2023:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482416</ArticleId><ArticleId IdType="pubmed">37680708</ArticleId></ArticleIdList></Reference><Reference><Citation>Long M, Park S-G, Strickland I, Hayden MS, Ghosh S. Nuclear factor-κB modulates regulatory T cell development by directly regulating expression of Foxp3 transcription factor. Immunity. 2009;31(6):921–931. doi:10.1016/j.immuni.2009.09.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.09.022</ArticleId><ArticleId IdType="pubmed">20064449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamaoka K, Saharinen P, Pesu M, Holt VE, Silvennoinen O, O’Shea JJ. The janus kinases (jaks). Genome Biol. 2004;5(12):1–6. doi:10.1186/gb-2004-5-12-253</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2004-5-12-253</ArticleId><ArticleId IdType="pmc">PMC545791</ArticleId><ArticleId IdType="pubmed">15575979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020;53(3):368–370. doi:10.1016/j.jmii.2020.03.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfitzner E, Kliem S, Baus D, Litterst M. The role of STATs in inflammation and inflammatory diseases. Curr Pharm Des. 2004;10(23):2839–2850. doi:10.2174/1381612043383638</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1381612043383638</ArticleId><ArticleId IdType="pubmed">15379672</ArticleId></ArticleIdList></Reference><Reference><Citation>de Prati AC, Ciampa AR, Cavalieri E, et al. STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem. 2005;12(16):1819–1828. doi:10.2174/0929867054546645</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867054546645</ArticleId><ArticleId IdType="pubmed">16101503</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker T, Stockinger S, Karaghiosoff M, Müller M, Kovarik P. IFNs and STATs in innate immunity to microorganisms. J Clin Invest. 2002;109(10):1271–1277. doi:10.1172/JCI0215770</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0215770</ArticleId><ArticleId IdType="pmc">PMC150987</ArticleId><ArticleId IdType="pubmed">12021240</ArticleId></ArticleIdList></Reference><Reference><Citation>Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181(7):1489–1501.e1415. doi:10.1016/j.cell.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7237901</ArticleId><ArticleId IdType="pubmed">32473127</ArticleId></ArticleIdList></Reference><Reference><Citation>Kisseleva T, Bhattacharya S, Braunstein J, Schindler C. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285(1–2):1–24. doi:10.1016/s0378-1119(02)00398-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0378-1119(02)00398-0</ArticleId><ArticleId IdType="pubmed">12039028</ArticleId></ArticleIdList></Reference><Reference><Citation>Sosonkina N, Starenki D, Park J-I. The role of STAT3 in thyroid cancer. Cancers (Basel). 2014;6(1):526–544. doi:10.3390/cancers6010526</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers6010526</ArticleId><ArticleId IdType="pmc">PMC3980610</ArticleId><ArticleId IdType="pubmed">24662939</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihara M, Ogura H, Ueda N, et al. IL-6–gp130–STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state. Int Immunol. 2007;19(6):695–702. doi:10.1093/intimm/dxm045</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxm045</ArticleId><ArticleId IdType="pubmed">17493959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotkowska A, Sewerynek E, Domańska D, Pastuszak-Lewandoska D, Brzeziańska E. Single nucleotide polymorphisms in the STAT3 gene influence AITD susceptibility, thyroid autoantibody levels, and IL6 and IL17 secretion. Cell. Mol. Biol. Lett. 2015;20(1):88–101. doi:10.1515/cmble-2015-0004</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cmble-2015-0004</ArticleId><ArticleId IdType="pubmed">26204395</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami M, Hirano T. A four-step model for the IL-6 amplifier, a regulator of chronic inflammations in tissue-specific MHC class II-associated autoimmune diseases. Front Immunol. 2011;2:22. doi:10.3389/fimmu.2011.00022</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2011.00022</ArticleId><ArticleId IdType="pmc">PMC3341963</ArticleId><ArticleId IdType="pubmed">22566812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J, Nakagiri T, Oto T, et al. IL-6 amplifier, NF-κB–triggered positive feedback for IL-6 signaling, in grafts is involved in allogeneic rejection responses. J Immunol. 2012;189(4):1928–1936. doi:10.4049/jimmunol.1103613</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1103613</ArticleId><ArticleId IdType="pubmed">22798669</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooke KR, Coghill JM, Serody JS. Chemokines and graft-versus-host disease. In: Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation. Elsevier; 2019:323–347.</Citation></Reference><Reference><Citation>Thalhamer T, McGrath M, Harnett M. MAPKs and their relevance to arthritis and inflammation. Rheumatology. 2008;47(4):409–414. doi:10.1093/rheumatology/kem297</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kem297</ArticleId><ArticleId IdType="pubmed">18187523</ArticleId></ArticleIdList></Reference><Reference><Citation>Noubade R, Krementsov DN, Del Rio R, et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood J Am Soc Hematol. 2011;118(12):3290–3300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3179398</ArticleId><ArticleId IdType="pubmed">21791428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajner SM, Goemann IM, Bueno AL, Larsen PR, Maia AL. IL-6 promotes nonthyroidal illness syndrome by blocking thyroxine activation while promoting thyroid hormone inactivation in human cells. J Clin Invest. 2011;121(5):1834–1845. doi:10.1172/JCI44678</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI44678</ArticleId><ArticleId IdType="pmc">PMC3083773</ArticleId><ArticleId IdType="pubmed">21540553</ArticleId></ArticleIdList></Reference><Reference><Citation>Romitti M, Wajner SM, Ceolin L, et al. MAPK and SHH pathways modulate type 3 deiodinase expression in papillary thyroid carcinoma. Endocr Relat Cancer. 2016;23(3):135–146. doi:10.1530/ERC-15-0162</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/ERC-15-0162</ArticleId><ArticleId IdType="pubmed">26825960</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma R, Traore K, Trush M, Rose N, Burek CL. Intracellular adhesion molecule-1 up-regulation on thyrocytes by iodine of non-obese diabetic. H2h4 mice is reactive oxygen species-dependent. Clin Exp Immunol. 2008;152(1):13–20. doi:10.1111/j.1365-2249.2008.03590.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2249.2008.03590.x</ArticleId><ArticleId IdType="pmc">PMC2384069</ArticleId><ArticleId IdType="pubmed">18241232</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzal S, Abdul Manap AS, Attiq A, Albokhadaim I, Kandeel M, Alhojaily SM. From imbalance to impairment: the central role of reactive oxygen species in oxidative stress-induced disorders and therapeutic exploration. Front Pharmacol. 2023;2023:14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10622810</ArticleId><ArticleId IdType="pubmed">37927596</ArticleId></ArticleIdList></Reference><Reference><Citation>Duntas LH. The catalytic role of iodine excess in loss of homeostasis in autoimmune thyroiditis. Curr Opin Endocrino. 2018;25(5):347–352. doi:10.1097/MED.0000000000000425</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MED.0000000000000425</ArticleId><ArticleId IdType="pubmed">30124478</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong W, Yang J, Bi Z, He C, Lei H, Yu W. A mouse model for SARS-CoV-2-induced acute respiratory distress syndrome. Signal Transduct Targ Ther. 2021;6(1):1–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775436</ArticleId><ArticleId IdType="pubmed">33384407</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.105954</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105954</ArticleId><ArticleId IdType="pmc">PMC7118634</ArticleId><ArticleId IdType="pubmed">32234467</ArticleId></ArticleIdList></Reference><Reference><Citation>Croce L, Gangemi D, Ancona G, et al. The cytokine storm and thyroid hormone changes in COVID-19. J Endocrinol Invest. 2021;44(5):891–904. doi:10.1007/s40618-021-01506-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-021-01506-7</ArticleId><ArticleId IdType="pmc">PMC7871522</ArticleId><ArticleId IdType="pubmed">33559848</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez C, Moran SA, Sereti I, et al. Graves’ disease after interleukin-2 therapy in a patient with human immunodeficiency virus infection. Thyroid. 2004;14(12):1097–1102. doi:10.1089/thy.2004.14.1097</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2004.14.1097</ArticleId><ArticleId IdType="pubmed">15650365</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon B-G, Takaki S, Miyake K, Takatsu K. The role of IL-5 for mature B-1 cells in homeostatic proliferation, cell survival, and Ig production. J Immunol. 2004;172(10):6020–6029. doi:10.4049/jimmunol.172.10.6020</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.172.10.6020</ArticleId><ArticleId IdType="pubmed">15128785</ArticleId></ArticleIdList></Reference><Reference><Citation>Wajner SM, Maia AL. New insights toward the acute non-thyroidal illness syndrome. Front Endocrinol. 2012;3:8. doi:10.3389/fendo.2012.00008</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2012.00008</ArticleId><ArticleId IdType="pmc">PMC3356062</ArticleId><ArticleId IdType="pubmed">22654851</ArticleId></ArticleIdList></Reference><Reference><Citation>Soehnlein O, Lindbom L, Weber C. Mechanisms underlying neutrophil-mediated monocyte recruitment. Blood J Am Soc Hematol. 2009;114(21):4613–4623.</Citation><ArticleIdList><ArticleId IdType="pubmed">19696199</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannino MH, Zhu Z, Xiao H, Bai Q, Wakefield MR, Fang Y. The paradoxical role of IL-10 in immunity and cancer. Cancer Lett. 2015;367(2):103–107. doi:10.1016/j.canlet.2015.07.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.canlet.2015.07.009</ArticleId><ArticleId IdType="pubmed">26188281</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan SM, Rapoport B. Prevention of autoantibody-mediated Graves’-like hyperthyroidism in mice with IL-4, a Th2 cytokine. J Immunol. 2003;170(7):3522–3527. doi:10.4049/jimmunol.170.7.3522</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.170.7.3522</ArticleId><ArticleId IdType="pubmed">12646613</ArticleId></ArticleIdList></Reference><Reference><Citation>Moens L, Tangye SG. Cytokine-mediated regulation of plasma cell generation: IL-21 takes center stage. Front Immunol. 2014;5:65. doi:10.3389/fimmu.2014.00065</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00065</ArticleId><ArticleId IdType="pmc">PMC3927127</ArticleId><ArticleId IdType="pubmed">24600453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezosi E, Wang SH, Utsugi S, et al. Interleukin-1beta and tumor necrosis factor (TNF)-alpha sensitize human thyroid epithelial cells to TNF-related apoptosis-inducing ligand-induced apoptosis through increases in procaspase-7 and Bid, and the down-regulation of p44/42 mitogen-activated protein kinase activity. J Clin Endocrinol Metab. 2004;89(1):250–257. doi:10.1210/jc.2003-030697</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2003-030697</ArticleId><ArticleId IdType="pubmed">14715858</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli A, Ferrari SM, Frascerra S, et al. Increase of circulating CXCL9 and CXCL11 associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis. J Clin Endocrinol Metab. 2011;96(6):1859–1863. doi:10.1210/jc.2010-2905</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2010-2905</ArticleId><ArticleId IdType="pubmed">21470996</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23–IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585–600. doi:10.1038/nri3707</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3707</ArticleId><ArticleId IdType="pmc">PMC4281037</ArticleId><ArticleId IdType="pubmed">25145755</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawashima A, Tanigawa K, Akama T, Yoshihara A, Ishii N, Suzuki K. Innate immune activation and thyroid autoimmunity. J Clin Endocrinol Metab. 2011;96(12):3661–3671. doi:10.1210/jc.2011-1568</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2011-1568</ArticleId><ArticleId IdType="pubmed">21956420</ArticleId></ArticleIdList></Reference><Reference><Citation>Marazuela M, Garcia-Lopez MA, Figueroa-Vega N, et al. Regulatory T cells in human autoimmune thyroid disease. J Clin Endocrinol Metab. 2006;91(9):3639–3646. doi:10.1210/jc.2005-2337</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2005-2337</ArticleId><ArticleId IdType="pubmed">16804051</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavsar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. Gen Meth Biomark Res Their Applic. 2015;2015:223.</Citation></Reference><Reference><Citation>Rotondi M, Chiovato L, Romagnani S, Serio M, Romagnani P. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520. doi:10.1210/er.2006-0044</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/er.2006-0044</ArticleId><ArticleId IdType="pubmed">17475924</ArticleId></ArticleIdList></Reference><Reference><Citation>Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14(5):409–426. doi:10.1016/S1359-6101(03)00049-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1359-6101(03)00049-2</ArticleId><ArticleId IdType="pubmed">12948524</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasmussen K, Bendtzen K, Feldt-Rasmussen U. Thyrocyte-interleukin-1 interactions. Exp Clin Endocrinol Diabetes. 2000;108(02):67–71. doi:10.1055/s-2000-5797</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2000-5797</ArticleId><ArticleId IdType="pubmed">10826510</ArticleId></ArticleIdList></Reference><Reference><Citation>Malik A, Kanneganti TD. Function and regulation of IL‐1α in inflammatory diseases and cancer. Immunol Rev. 2018;281(1):124–137. doi:10.1111/imr.12615</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12615</ArticleId><ArticleId IdType="pmc">PMC5739076</ArticleId><ArticleId IdType="pubmed">29247991</ArticleId></ArticleIdList></Reference><Reference><Citation>Giordano C, Stassi G, De Maria R, et al. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis. Science. 1997;275:5302):960–963. doi:10.1126/science.275.5302.960</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.275.5302.960</ArticleId><ArticleId IdType="pubmed">9020075</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner S, Miller JH. Brenner’s Encyclopedia of Genetics. Elsevier Science; 2014.</Citation></Reference><Reference><Citation>Yang S, Wang J, Brand DD, Zheng SG. Role of TNF–TNF receptor 2 signal in regulatory T cells and its therapeutic implications. Front Immunol. 2018;9:784. doi:10.3389/fimmu.2018.00784</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00784</ArticleId><ArticleId IdType="pmc">PMC5916970</ArticleId><ArticleId IdType="pubmed">29725328</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee HJ, Lombardi A, Stefan M, et al. Cd40 signaling in graves disease is mediated through canonical and noncanonical thyroidal nuclear factor κ b activation. Endocrinology. 2017;158(2):410–418. doi:10.1210/en.2016-1609</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2016-1609</ArticleId><ArticleId IdType="pmc">PMC5413074</ArticleId><ArticleId IdType="pubmed">27929668</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson E, Huber A, Akeno N, et al. A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression. Genes Immun. 2007;8(3):205–214. doi:10.1038/sj.gene.6364375</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.gene.6364375</ArticleId><ArticleId IdType="pubmed">17344890</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrari SM, Ruffilli I, Elia G, et al. Chemokines in hyperthyroidism. J Clin Translat Endocrinol. 2019;16:100196. doi:10.1016/j.jcte.2019.100196</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcte.2019.100196</ArticleId><ArticleId IdType="pmc">PMC6536457</ArticleId><ArticleId IdType="pubmed">31193493</ArticleId></ArticleIdList></Reference><Reference><Citation>Boye K, Billottet C, Pujol N, Alves I, Bikfalvi A. Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR). Sci Rep. 2017;7(1):1–11. doi:10.1038/s41598-017-11151-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-11151-x</ArticleId><ArticleId IdType="pmc">PMC5587768</ArticleId><ArticleId IdType="pubmed">28878333</ArticleId></ArticleIdList></Reference><Reference><Citation>Coperchini F, Chiovato L, Rotondi M. Interleukin-6, CXCL10 and infiltrating macrophages in COVID-19-related cytokine storm: not one for all but all for one! Front Immunol. 2021;12:668507. doi:10.3389/fimmu.2021.668507</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.668507</ArticleId><ArticleId IdType="pmc">PMC8107352</ArticleId><ArticleId IdType="pubmed">33981314</ArticleId></ArticleIdList></Reference><Reference><Citation>Dembic Z. The Cytokines of the Immune System: The Role of Cytokines in Disease Related to Immune Response. Academic Press; 2015.</Citation></Reference><Reference><Citation>Docter R, Krenning E, De Jong M, Hennemann G. The sick euthyroid syndrome: changes in thyroid hormone serum parameters and hormone metabolism. Clin Endocrinol. 1993;39(5):499–518. doi:10.1111/j.1365-2265.1993.tb02401.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2265.1993.tb02401.x</ArticleId><ArticleId IdType="pubmed">8252737</ArticleId></ArticleIdList></Reference><Reference><Citation>de Vries EM, Fliers E, Boelen A. The molecular basis of the non-thyroidal illness syndrome. J Endocrinol. 2015;225(3):R67–81. doi:10.1530/JOE-15-0133</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-15-0133</ArticleId><ArticleId IdType="pubmed">25972358</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou R, Wu C, Zhang S, et al. Euthyroid sick syndrome in patients with COVID-19. Front Endocrinol. 2020;11:566439. doi:10.3389/fendo.2020.566439</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2020.566439</ArticleId><ArticleId IdType="pmc">PMC7575767</ArticleId><ArticleId IdType="pubmed">33117282</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi-Tezuka M, Yoshida Y, Fukada T, et al. Gab1 acts as an adapter molecule linking the cytokine receptor gp130 to ERK mitogen-activated protein kinase. Mol Cell Biol. 1998;18(7):4109–4117. doi:10.1128/MCB.18.7.4109</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/MCB.18.7.4109</ArticleId><ArticleId IdType="pmc">PMC108995</ArticleId><ArticleId IdType="pubmed">9632795</ArticleId></ArticleIdList></Reference><Reference><Citation>Kester MH, Kuiper GG, Versteeg R, Visser TJ. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology. 2006;147(12):5845–5854. doi:10.1210/en.2006-0590</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2006-0590</ArticleId><ArticleId IdType="pubmed">16935842</ArticleId></ArticleIdList></Reference><Reference><Citation>Baqui M, Botero D, Gereben B, et al. Human type 3 iodothyronine selenodeiodinase is located in the plasma membrane and undergoes rapid internalization to endosomes. J Biol Chem. 2003;278(2):1206–1211. doi:10.1074/jbc.M210266200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M210266200</ArticleId><ArticleId IdType="pubmed">12419801</ArticleId></ArticleIdList></Reference><Reference><Citation>Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med. 2001;30(11):1191–1212. doi:10.1016/S0891-5849(01)00480-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(01)00480-4</ArticleId><ArticleId IdType="pubmed">11368918</ArticleId></ArticleIdList></Reference><Reference><Citation>Attiq A, Jalil J, Husain K, Mohamad HF, Ahmad A. Luteolin and apigenin derived glycosides from Alphonsea elliptica abrogate LPS-induced inflammatory responses in human plasma. J Ethnopharmacol. 2021;275:114120. doi:10.1016/j.jep.2021.114120</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jep.2021.114120</ArticleId><ArticleId IdType="pubmed">33857595</ArticleId></ArticleIdList></Reference><Reference><Citation>Attiq A, Jalil J, Husain K, Jamal JA, Ismail EN. A new prenylated benzoquinone from Cyathocalyx pruniferus abrogates LPS-induced inflammatory responses associated with PGE2, COX-2 and cytokines biosynthesis in human plasma. Inflammopharmacology. 2021;29(3):841–854. doi:10.1007/s10787-021-00807-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-021-00807-w</ArticleId><ArticleId IdType="pubmed">33864564</ArticleId></ArticleIdList></Reference><Reference><Citation>Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84. doi:10.1016/j.biocel.2006.07.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2006.07.001</ArticleId><ArticleId IdType="pubmed">16978905</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras VM, Van Herck SL. Iodothyronine deiodinase structure and function: from ascidians to humans. J Endocrinol. 2012;215(2):189–206. doi:10.1530/JOE-12-0204</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-12-0204</ArticleId><ArticleId IdType="pubmed">22825922</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiper GG, Klootwijk W, Visser TJ. Substitution of cysteine for a conserved alanine residue in the catalytic center of type II iodothyronine deiodinase alters interaction with reducing cofactor. Endocrinology. 2002;143(4):1190–1198. doi:10.1210/endo.143.4.8738</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo.143.4.8738</ArticleId><ArticleId IdType="pubmed">11897672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen I-Y, Moriyama M, Chang M-F, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50. doi:10.3389/fmicb.2019.00050</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2019.00050</ArticleId><ArticleId IdType="pmc">PMC6361828</ArticleId><ArticleId IdType="pubmed">30761102</ArticleId></ArticleIdList></Reference><Reference><Citation>Brigelius-Flohé R, Banning A, Kny M, Böl G-F. Redox events in interleukin-1 signaling. Arch Biochem Biophys. 2004;423(1):66–73. doi:10.1016/j.abb.2003.12.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.abb.2003.12.008</ArticleId><ArticleId IdType="pubmed">14989266</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagaya T, Fujieda M, Otsuka G, Yang J-P, Okamoto T, Seo H. A potential role of activated NF-κB in the pathogenesis of euthyroid sick syndrome. J Clin Invest. 2000;106(3):393–402. doi:10.1172/JCI7771</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI7771</ArticleId><ArticleId IdType="pmc">PMC314321</ArticleId><ArticleId IdType="pubmed">10930442</ArticleId></ArticleIdList></Reference><Reference><Citation>Tee LY, Harjanto S, Rosario BH. COVID-19 complicated by Hashimoto’s thyroiditis. Singapore Med J. 2020;62(5):265. doi:10.11622/smedj.2020106</Citation><ArticleIdList><ArticleId IdType="doi">10.11622/smedj.2020106</ArticleId><ArticleId IdType="pmc">PMC8801861</ArticleId><ArticleId IdType="pubmed">32668831</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesh BB, Bhattacharya P, Gopisetty A, Prabhakar BS. Role of cytokines in the pathogenesis and suppression of thyroid autoimmunity. J Interferon Cytokine Res. 2011;31(10):721–731. doi:10.1089/jir.2011.0049</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2011.0049</ArticleId><ArticleId IdType="pmc">PMC3189552</ArticleId><ArticleId IdType="pubmed">21823922</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyzik A, Grywalska E, Matyjaszek-Matuszek B, Roliński J. Immune disorders in Hashimoto’s thyroiditis: what do we know so far? J Immunol Res. 2015;2015:1–8. doi:10.1155/2015/979167</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/979167</ArticleId><ArticleId IdType="pmc">PMC4426893</ArticleId><ArticleId IdType="pubmed">26000316</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikoś H, Mikoś M, Obara-Moszyńska M, Niedziela M. The role of the immune system and cytokines involved in the pathogenesis of autoimmune thyroid disease (AITD). Endokrynol Pol. 2014;65(2):150–155. doi:10.5603/EP.2014.0021</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/EP.2014.0021</ArticleId><ArticleId IdType="pubmed">24802739</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochman J, Jakubczyk K, Bargiel P, Janda-Milczarek K. The influence of oxidative stress on thyroid diseases. Antioxidants. 2021;10(9):1442. doi:10.3390/antiox10091442</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10091442</ArticleId><ArticleId IdType="pmc">PMC8465820</ArticleId><ArticleId IdType="pubmed">34573074</ArticleId></ArticleIdList></Reference><Reference><Citation>Corssmit E, De Metz J, Sauerwein H, Romijn J. Biologic responses to IFN-α administration in humans. J Interferon Cytokine Res. 2000;20(12):1039–1047. doi:10.1089/107999000750053690</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/107999000750053690</ArticleId><ArticleId IdType="pubmed">11152569</ArticleId></ArticleIdList></Reference><Reference><Citation>Prummel MF, Wiersinga WM. Thyroid peroxidase autoantibodies in euthyroid subjects. Best Pract Res Clin Endocrinol Metab. 2005;19(1):1–15. doi:10.1016/j.beem.2004.11.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2004.11.003</ArticleId><ArticleId IdType="pubmed">15826919</ArticleId></ArticleIdList></Reference><Reference><Citation>Teillaud J-L. Antibody-dependent cellular cytotoxicity (ADCC). eLS; 2012.</Citation></Reference><Reference><Citation>Wang SH, Baker JR Jr. The role of apoptosis in thyroid autoimmunity. Thyroid. 2007;17(10):975–979. doi:10.1089/thy.2007.0208</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/thy.2007.0208</ArticleId><ArticleId IdType="pubmed">17900237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran SE, Holmström TH, Ahonen M, Kähäri V-M, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem. 2001;276(19):16484–16490. doi:10.1074/jbc.M010384200</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M010384200</ArticleId><ArticleId IdType="pubmed">11278665</ArticleId></ArticleIdList></Reference><Reference><Citation>Hussein MR, Haemel AK, Wood GS. Apoptosis and melanoma: molecular mechanisms. J Pathol. 2003;199(3):275–288. doi:10.1002/path.1300</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.1300</ArticleId><ArticleId IdType="pubmed">12579529</ArticleId></ArticleIdList></Reference><Reference><Citation>Mezosi E, Wang SH, Utsugi S, et al. Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells. Mol Endocrinol. 2005;19(3):804–811. doi:10.1210/me.2004-0286</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/me.2004-0286</ArticleId><ArticleId IdType="pubmed">15563545</ArticleId></ArticleIdList></Reference><Reference><Citation>W-p Z, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell. 1997;89(4):587–596. doi:10.1016/S0092-8674(00)80240-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0092-8674(00)80240-8</ArticleId><ArticleId IdType="pubmed">9160750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiromatsu Y, Kaku H, Mukai T, et al. Immunohistochemical analysis of bcl-2, Bax and Bak expression in thyroid glands from patients with Graves’ disease. Endocr J. 2004;51(4):399–405. doi:10.1507/endocrj.51.399</Citation><ArticleIdList><ArticleId IdType="doi">10.1507/endocrj.51.399</ArticleId><ArticleId IdType="pubmed">15351796</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuryłowicz A, Nauman J. The role of nuclear factor-kappaB in the development of autoimmune diseases: a link between genes and environment. Acta Biochim Pol. 2008;55(4):629–647. doi:10.18388/abp.2008_3023</Citation><ArticleIdList><ArticleId IdType="doi">10.18388/abp.2008_3023</ArticleId><ArticleId IdType="pubmed">19081854</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirata Y, Takahashi M, Morishita T, Noguchi T, Matsuzawa A. Post-translational modifications of the TAK1-TAB complex. Int J Mol Sci. 2017;18(1):205. doi:10.3390/ijms18010205</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18010205</ArticleId><ArticleId IdType="pmc">PMC5297835</ArticleId><ArticleId IdType="pubmed">28106845</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanafusa T, Chiovato L, Doniach D, Pujol-Borrell R, Russell R, Bottazzo G. ABERRANT EXPRESSION OF HLA-DR ANTIGEN ON THYROCYTES IN GRAVES’DISEASE: RELEVANCE FOR AUTOIMMUNITY. Lancet. 1983;322(8359):1111–1115. doi:10.1016/S0140-6736(83)90628-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(83)90628-1</ArticleId><ArticleId IdType="pubmed">6138646</ArticleId></ArticleIdList></Reference><Reference><Citation>Faure GC, Bensoussan-Lejzerowicz D, Bene MC, Aubert V, Leclere J. Coexpression of CD40 and class II antigen HLA-DR in Graves’ disease thyroid epithelial cells. Clin immunol immunopathol. 1997;84(2):212–215. doi:10.1006/clin.1997.4391</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1997.4391</ArticleId><ArticleId IdType="pubmed">9245555</ArticleId></ArticleIdList></Reference><Reference><Citation>Zazzeroni F, Papa S, Algeciras-Schimnich A, et al. Gadd45β mediates the protective effects of CD40 costimulation against Fas-induced apoptosis. Blood. 2003;102(9):3270–3279. doi:10.1182/blood-2003-03-0689</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2003-03-0689</ArticleId><ArticleId IdType="pubmed">12855571</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolls JK, Lindén A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467–476. doi:10.1016/j.immuni.2004.08.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2004.08.018</ArticleId><ArticleId IdType="pubmed">15485625</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghoreschi K, Laurence A, Yang X-P, et al. Generation of pathogenic TH17 cells in the absence of TGF-β signalling. Nature. 2010;467:7318):967–971. doi:10.1038/nature09447</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature09447</ArticleId><ArticleId IdType="pmc">PMC3108066</ArticleId><ArticleId IdType="pubmed">20962846</ArticleId></ArticleIdList></Reference><Reference><Citation>Lui DTW, Lee CH, Chow WS, et al. Thyroid dysfunction in relation to immune profile, disease status, and outcome in 191 patients with COVID-19. J Clin Endocrinol Metab. 2021;106(2):e926–e935. doi:10.1210/clinem/dgaa813</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/clinem/dgaa813</ArticleId><ArticleId IdType="pmc">PMC7665541</ArticleId><ArticleId IdType="pubmed">33141191</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber AK, Finkelman FD, Li CW, et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J Immunol. 2012;189(6):3043–3053. doi:10.4049/jimmunol.1200311</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1200311</ArticleId><ArticleId IdType="pmc">PMC3436983</ArticleId><ArticleId IdType="pubmed">22888137</ArticleId></ArticleIdList></Reference><Reference><Citation>Woeller CF, Roztocil E, Hammond C, Feldon SE. TSHR signaling stimulates proliferation through PI3K/Akt and induction of miR-146a and miR-155 in thyroid eye disease orbital fibroblasts. Invest Ophthalmol Vis Sci. 2019;60(13):4336–4345. doi:10.1167/iovs.19-27865</Citation><ArticleIdList><ArticleId IdType="doi">10.1167/iovs.19-27865</ArticleId><ArticleId IdType="pmc">PMC6798326</ArticleId><ArticleId IdType="pubmed">31622470</ArticleId></ArticleIdList></Reference><Reference><Citation>Michalek K, Morshed SA, Latif R, Davies TF. TSH receptor autoantibodies. Autoimmun Rev. 2009;9(2):113–116. doi:10.1016/j.autrev.2009.03.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2009.03.012</ArticleId><ArticleId IdType="pmc">PMC3753030</ArticleId><ArticleId IdType="pubmed">19332151</ArticleId></ArticleIdList></Reference><Reference><Citation>Morshed SA, Latif R, Davies TF. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology. 2009;150(1):519–529. doi:10.1210/en.2008-0878</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2008-0878</ArticleId><ArticleId IdType="pmc">PMC2630889</ArticleId><ArticleId IdType="pubmed">18719020</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller I, Cannavaro D, Dazzi D, et al. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020;8(9):739–741. doi:10.1016/S2213-8587(20)30266-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(20)30266-7</ArticleId><ArticleId IdType="pmc">PMC7392564</ArticleId><ArticleId IdType="pubmed">32738929</ArticleId></ArticleIdList></Reference><Reference><Citation>Carella C, Mazziotti G, Amato G, Braverman L, Roti E. Interferon-α-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. J Clin Endocrinol Metab. 2004;89(8):3656–3661. doi:10.1210/jc.2004-0627</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2004-0627</ArticleId><ArticleId IdType="pubmed">15292282</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce EN, Farwell AP, Braverman LE. Thyroiditis. N Engl J Med. 2003;348(26):2646–2655. doi:10.1056/NEJMra021194</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra021194</ArticleId><ArticleId IdType="pubmed">12826640</ArticleId></ArticleIdList></Reference><Reference><Citation>Truran P, Aspinall S. Thyrotoxicosis and thyroiditis. Surgery. 2014;32(10):537–542. doi:10.1016/j.mpsur.2014.07.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mpsur.2014.07.006</ArticleId></ArticleIdList></Reference><Reference><Citation>Asfuroglu Kalkan E, Ates I. A case of subacute thyroiditis associated with Covid-19 infection. J Endocrinol Invest. 2020;43(8):1173–1174. doi:10.1007/s40618-020-01316-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40618-020-01316-3</ArticleId><ArticleId IdType="pmc">PMC7273820</ArticleId><ArticleId IdType="pubmed">32504458</ArticleId></ArticleIdList></Reference><Reference><Citation>Volpé R. Thyroiditis: current views of pathogenesis. Med Clin North Am. 1975;59(5):1163–1175. doi:10.1016/S0025-7125(16)31965-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0025-7125(16)31965-4</ArticleId><ArticleId IdType="pubmed">1099362</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakravarthy V, Ejaz S. Thyroxine-binding globulin deficiency; 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31334994</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Marco F, Foti G, Corsico A. Where are we with the use of N-acetylcysteine as a preventive and adjuvant treatment for COVID-19. Eur Rev Med Pharmacol Sci. 2022;26(2):715–721. doi:10.26355/eurrev_202201_27898</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202201_27898</ArticleId><ArticleId IdType="pubmed">35113447</ArticleId></ArticleIdList></Reference><Reference><Citation>Maia AL, Goemann IM, Meyer EL, Wajner SM. Deiodinases: the balance of thyroid hormone: type 1 iodothyronine deiodinase in human physiology and disease. J Endocrinol. 2011;209(3):283–297. doi:10.1530/JOE-10-0481</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-10-0481</ArticleId><ArticleId IdType="pubmed">21415143</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehnen TE, Santos MV, Lima A, Maia AL, Wajner SM. N-acetylcysteine prevents low T3 syndrome and attenuates cardiac dysfunction in a male rat model of myocardial infarction. Endocrinology. 2017;158(5):1502–1510. doi:10.1210/en.2016-1586</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/en.2016-1586</ArticleId><ArticleId IdType="pubmed">28323971</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrocco I, Altieri F, Peluso I. Measurement and clinical significance of biomarkers of oxidative stress in humans. Oxid Med Cell Longev. 2017;2017. doi:10.1155/2017/6501046</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/6501046</ArticleId><ArticleId IdType="pmc">PMC5494111</ArticleId><ArticleId IdType="pubmed">28698768</ArticleId></ArticleIdList></Reference><Reference><Citation>Vidart J, Wajner SM, Leite RS, et al. N-acetylcysteine administration prevents nonthyroidal illness syndrome in patients with acute myocardial infarction: a randomized clinical trial. J Clin Endocrinol Metab. 2014;99(12):4537–4545. doi:10.1210/jc.2014-2192</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2014-2192</ArticleId><ArticleId IdType="pmc">PMC4255112</ArticleId><ArticleId IdType="pubmed">25148231</ArticleId></ArticleIdList></Reference><Reference><Citation>De Flora S, Balansky R, La Maestra S. Rationale for the use of N‐acetylcysteine in both prevention and adjuvant therapy of COVID‐19. THE FASEB Journal. 2020;34(10):13185–13193. doi:10.1096/fj.202001807</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202001807</ArticleId><ArticleId IdType="pmc">PMC7436914</ArticleId><ArticleId IdType="pubmed">32780893</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharya R, Mondal M, Naiya SB, Lyngdoh L, Mukherjee R, Singh PK. The beneficial role of N-acetylcysteine as an adjunctive drug in treatment of COVID-19 patients in a tertiary care hospital in India: an observational study. Int J Res Med Sci. 2020;8(10):1. doi:10.18203/2320-6012.ijrms20204010</Citation><ArticleIdList><ArticleId IdType="doi">10.18203/2320-6012.ijrms20204010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859–866. doi:10.1136/annrheumdis-2020-217871</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217871</ArticleId><ArticleId IdType="pmc">PMC7299648</ArticleId><ArticleId IdType="pubmed">32471903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ungaro RC, Brenner EJ, Agrawal M, et al. Impact of medications on COVID-19 outcomes in inflammatory bowel disease: analysis of more than 6000 patients from an international registry. Gastroenterology. 2022;162(1):316–319.e315. doi:10.1053/j.gastro.2021.09.011</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.09.011</ArticleId><ArticleId IdType="pmc">PMC8437703</ArticleId><ArticleId IdType="pubmed">34529987</ArticleId></ArticleIdList></Reference><Reference><Citation>Leone GM, Mangano K, Petralia MC, Nicoletti F, Past FP. Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy. J Clin Med. 2023;12(4):1630. doi:10.3390/jcm12041630</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12041630</ArticleId><ArticleId IdType="pmc">PMC9963154</ArticleId><ArticleId IdType="pubmed">36836166</ArticleId></ArticleIdList></Reference><Reference><Citation>Queiroz NS, Martins CA, Quaresma AB, et al. COVID‐19 outcomes in patients with inflammatory bowel diseases in Latin America: results from SECURE‐IBD registry. J Gastroenterol Hepatol. 2021;36(11):3033–3040. doi:10.1111/jgh.15588</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgh.15588</ArticleId><ArticleId IdType="pmc">PMC8447321</ArticleId><ArticleId IdType="pubmed">34151470</ArticleId></ArticleIdList></Reference><Reference><Citation>Sparks JA, Wallace ZS, Seet AM, et al. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. Ann Rheum Dis. 2021;80(9):1137–1146. doi:10.1136/annrheumdis-2021-220418</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220418</ArticleId><ArticleId IdType="pmc">PMC8172266</ArticleId><ArticleId IdType="pubmed">34049860</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC. Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2022;71(7):1426–1439. doi:10.1136/gutjnl-2021-326784</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2021-326784</ArticleId><ArticleId IdType="pmc">PMC9185820</ArticleId><ArticleId IdType="pubmed">35477864</ArticleId></ArticleIdList></Reference><Reference><Citation>Edelman-Klapper H, Zittan E, Shitrit AB-G, et al. Lower serologic response to COVID-19 mRNA vaccine in patients with inflammatory bowel diseases treated with anti-TNFα. Gastroenterology. 2022;162(2):454–467. doi:10.1053/j.gastro.2021.10.029</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2021.10.029</ArticleId><ArticleId IdType="pmc">PMC8552587</ArticleId><ArticleId IdType="pubmed">34717923</ArticleId></ArticleIdList></Reference><Reference><Citation>Scavone C, Mascolo A, Rafaniello C, et al. Therapeutic strategies to fight COVID‐19: which is the status artis? Br J Pharmacol. 2022;179(10):2128–2148. doi:10.1111/bph.15452</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15452</ArticleId><ArticleId IdType="pmc">PMC8239658</ArticleId><ArticleId IdType="pubmed">33960398</ArticleId></ArticleIdList></Reference><Reference><Citation>Bessler H, Mendel C, Straussberg R, Gurary N, Aloni D, Sirota L. Effects of dexamethasone on IL-1β, IL-6, and TNF-α production by mononuclear cells of newborns and adults. Neonatology. 1999;75(4):225–233. doi:10.1159/000014099</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000014099</ArticleId><ArticleId IdType="pubmed">10026370</ArticleId></ArticleIdList></Reference><Reference><Citation>Oeckinghaus A, Ghosh S. The NF-κB family of transcription factors and its regulation. Cold Spring Harb Perspect Biol. 2009;1(4):a000034. doi:10.1101/cshperspect.a000034</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a000034</ArticleId><ArticleId IdType="pmc">PMC2773619</ArticleId><ArticleId IdType="pubmed">20066092</ArticleId></ArticleIdList></Reference><Reference><Citation>Aghai ZH, Kumar S, Farhath S, et al. Dexamethasone suppresses expression of Nuclear Factor-kappaB in the cells of tracheobronchial lavage fluid in premature neonates with respiratory distress. Pediatr Res. 2006;59(6):811–815. doi:10.1203/01.pdr.0000219120.92049.b3</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/01.pdr.0000219120.92049.b3</ArticleId><ArticleId IdType="pubmed">16641216</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson G, Wilde GJ, Spiller DG, et al. NF-κB signalling is inhibited by glucocorticoid receptor and STAT6 via distinct mechanisms. J Cell Sci. 2003;116(12):2495–2503. doi:10.1242/jcs.00461</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.00461</ArticleId><ArticleId IdType="pubmed">12734399</ArticleId></ArticleIdList></Reference><Reference><Citation>Group TRC. Dexamethasone in hospitalized patients with Covid-19—preliminary report. New Engl J Med. 2020;2020:1.</Citation></Reference><Reference><Citation>Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab. 2009;23(6):793–800. doi:10.1016/j.beem.2009.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beem.2009.08.003</ArticleId><ArticleId IdType="pmc">PMC2784889</ArticleId><ArticleId IdType="pubmed">19942154</ArticleId></ArticleIdList></Reference><Reference><Citation>Alkemade A, Unmehopa U, Wiersinga W, Swaab D, Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J Clin Endocrinol Metab. 2005;90(1):323–327. doi:10.1210/jc.2004-1430</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2004-1430</ArticleId><ArticleId IdType="pubmed">15509645</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest. 1969;48(11):2096–2103. doi:10.1172/JCI106176</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI106176</ArticleId><ArticleId IdType="pmc">PMC297463</ArticleId><ArticleId IdType="pubmed">4980930</ArticleId></ArticleIdList></Reference><Reference><Citation>John C, Christian H, Morris J, Flower R, Solito E, Buckingham J. Kinase‐dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptides. J Neuroendocrinol. 2003;15(10):946–957. doi:10.1046/j.1365-2826.2003.01081.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2826.2003.01081.x</ArticleId><ArticleId IdType="pubmed">12969239</ArticleId></ArticleIdList></Reference><Reference><Citation>Cote-Vélez A, Pérez-Martínez L, Charli J-L, Joseph-Bravo P. The PKC and ERK/MAPK pathways regulate glucocorticoid action on TRH transcription. Neurochem Res. 2008;33(8):1582–1591. doi:10.1007/s11064-008-9698-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9698-5</ArticleId><ArticleId IdType="pubmed">18427988</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao L, Su J, Liu S, et al. MAP kinase phosphatase MKP-1 regulates p-ERK1/2 signaling pathway with fluoride treatment. Biochem Biophys Res Commun. 2021;542:65–72. doi:10.1016/j.bbrc.2020.12.100</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2020.12.100</ArticleId><ArticleId IdType="pubmed">33493990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kassel O, Sancono A, Krätzschmar J, Kreft B, Stassen M, Cato AC. Glucocorticoids inhibit MAP kinase via increased expression and decreased degradation of MKP-1. EMBO J. 2001;20(24):7108–7116. doi:10.1093/emboj/20.24.7108</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/20.24.7108</ArticleId><ArticleId IdType="pmc">PMC125780</ArticleId><ArticleId IdType="pubmed">11742987</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph-Bravo P, Jaimes-Hoy L, Charli J-L. Regulation of TRH neurons and energy homeostasis-related signals under stress. J Endocrinol. 2015;224(3):R139–R159. doi:10.1530/JOE-14-0593</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/JOE-14-0593</ArticleId><ArticleId IdType="pubmed">25563352</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo W, Li Y-X, Jiang L-J, Chen Q, Wang T, Ye D-W. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020;41(8):531–543. doi:10.1016/j.tips.2020.06.007</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.06.007</ArticleId><ArticleId IdType="pmc">PMC7298494</ArticleId><ArticleId IdType="pubmed">32580895</ArticleId></ArticleIdList></Reference><Reference><Citation>Satarker S, Tom AA, Shaji RA, Alosious A, Luvis M, Nampoothiri M. JAK-STAT pathway inhibition and their implications in COVID-19 therapy. Postgrad Med. 2021;133(5):489–507. doi:10.1080/00325481.2020.1855921</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2020.1855921</ArticleId><ArticleId IdType="pmc">PMC7784782</ArticleId><ArticleId IdType="pubmed">33245005</ArticleId></ArticleIdList></Reference><Reference><Citation>Keystone EC, Taylor PC, Drescher E, et al. Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis. 2015;74(2):333–340. doi:10.1136/annrheumdis-2014-206478</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2014-206478</ArticleId><ArticleId IdType="pmc">PMC4316868</ArticleId><ArticleId IdType="pubmed">25431052</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorrell FJ, Szklarz M, Azeez KRA, Elkins JM, Knapp S. Family-wide structural analysis of human numb-associated protein kinases. Structure. 2016;24(3):401–411. doi:10.1016/j.str.2015.12.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2015.12.015</ArticleId><ArticleId IdType="pmc">PMC4780864</ArticleId><ArticleId IdType="pubmed">26853940</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment?–Authors’ reply. Lancet Infect Dis. 2020;20(9):1013–1014. doi:10.1016/S1473-3099(20)30270-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30270-X</ArticleId><ArticleId IdType="pmc">PMC7271155</ArticleId><ArticleId IdType="pubmed">32251639</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402. doi:10.1016/S1473-3099(20)30132-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30132-8</ArticleId><ArticleId IdType="pmc">PMC7158903</ArticleId><ArticleId IdType="pubmed">32113509</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillenwater S, Rahaghi F, Hadeh A. Remdesivir for the treatment of Covid-19-preliminary report. N Engl J Med. 2020;383(10):992.</Citation><ArticleIdList><ArticleId IdType="pubmed">32649074</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullard A. Ebola outbreak prompts experimental drug rollout. Nat Rev Drug Discov. 2018;17(7):460–461.</Citation><ArticleIdList><ArticleId IdType="pubmed">29950712</ArticleId></ArticleIdList></Reference><Reference><Citation>Agostini ML, Andres EL, Sims AC, et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221–00218. doi:10.1128/mBio.00221-18</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00221-18</ArticleId><ArticleId IdType="pmc">PMC5844999</ArticleId><ArticleId IdType="pubmed">29511076</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren TK, Jordan R, Lo MK, et al. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature. 2016;531(7594):381–385. doi:10.1038/nature17180</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature17180</ArticleId><ArticleId IdType="pmc">PMC5551389</ArticleId><ArticleId IdType="pubmed">26934220</ArticleId></ArticleIdList></Reference><Reference><Citation>Arshad U, Pertinez H, Box H, et al. Prioritization of anti‐SARS‐Cov‐2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics. Clin Pharmacol Ther. 2020;108(4):775–790. doi:10.1002/cpt.1909</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1909</ArticleId><ArticleId IdType="pmc">PMC7280633</ArticleId><ArticleId IdType="pubmed">32438446</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021;384(9):795–807. doi:10.1056/NEJMoa2031994</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId><ArticleId IdType="pmc">PMC7745180</ArticleId><ArticleId IdType="pubmed">33306283</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitiello A, Ferrara F. Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection. Mol Biol Rep. 2022;49(1):827–831. doi:10.1007/s11033-021-06888-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11033-021-06888-8</ArticleId><ArticleId IdType="pmc">PMC8627294</ArticleId><ArticleId IdType="pubmed">34839450</ArticleId></ArticleIdList></Reference><Reference><Citation>Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19–A systematic review. Life Sci. 2020;254:117788. doi:10.1016/j.lfs.2020.117788</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lfs.2020.117788</ArticleId><ArticleId IdType="pmc">PMC7219356</ArticleId><ArticleId IdType="pubmed">32475810</ArticleId></ArticleIdList></Reference><Reference><Citation>Poggiali E, Zaino D, Immovilli P, et al. Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients. Clin Chim Acta. 2020;509:135–138. doi:10.1016/j.cca.2020.06.012</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.06.012</ArticleId><ArticleId IdType="pmc">PMC7282743</ArticleId><ArticleId IdType="pubmed">32531257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabbatino F, Conti V, Franci G, et al. PD-L1 dysregulation in COVID-19 patients. Front Immunol. 2021;12:695242. doi:10.3389/fimmu.2021.695242</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.695242</ArticleId><ArticleId IdType="pmc">PMC8215357</ArticleId><ArticleId IdType="pubmed">34163490</ArticleId></ArticleIdList></Reference><Reference><Citation>Sambugaro G, Brambilla E, Costanzo G, et al. COVID-19 Clinical Features and Outcome in Italian Patients Treated with Biological Drugs Targeting Type 2 Inflammation. Life. 2024;14(3):378. doi:10.3390/life14030378</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life14030378</ArticleId><ArticleId IdType="pmc">PMC10971220</ArticleId><ArticleId IdType="pubmed">38541703</ArticleId></ArticleIdList></Reference><Reference><Citation>Penman SL, Kiy RT, Jensen RL, et al. Safety perspectives on presently considered drugs for the treatment of COVID‐19. Br J Pharmacol. 2020;177(19):4353–4374. doi:10.1111/bph.15204</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.15204</ArticleId><ArticleId IdType="pmc">PMC7404855</ArticleId><ArticleId IdType="pubmed">32681537</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinella MA. Routine antiemetic prophylaxis with dexamethasone during COVID-19: should oncologists reconsider? J Oncol Pharm Pract. 2020;26(6):1482–1485. doi:10.1177/1078155220931921</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1078155220931921</ArticleId><ArticleId IdType="pubmed">32507102</ArticleId></ArticleIdList></Reference><Reference><Citation>Prentice RE, Al‐Ani A, Christensen B. Managing COVID‐19 in patients with inflammatory bowel disease: navigating unprecedented challenges. Intern Med J. 2021;51(2):284–287. doi:10.1111/imj.15190</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imj.15190</ArticleId><ArticleId IdType="pmc">PMC8013000</ArticleId><ArticleId IdType="pubmed">33631857</ArticleId></ArticleIdList></Reference><Reference><Citation>Y-N N, Chen G, Sun J, Liang B-M, Liang Z-A. The effect of corticosteroids on mortality of patients with influenza pneumonia: a systematic review and meta-analysis. Critical Care. 2019;23(1):1–9. doi:10.1186/s13054-018-2293-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-018-2293-5</ArticleId><ArticleId IdType="pmc">PMC6437920</ArticleId><ArticleId IdType="pubmed">30917856</ArticleId></ArticleIdList></Reference><Reference><Citation>Dixit D, Kuete NT, Bene P, Khan I, Oprea-Ilies G, Flenaugh E. invasive pulmonary aspergillosis with hydropneumothorax in a patient taking high-dose glucocorticoids. Am J Case Rep. 2020;21:e928499–928491. doi:10.12659/AJCR.928499</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/AJCR.928499</ArticleId><ArticleId IdType="pmc">PMC7774990</ArticleId><ArticleId IdType="pubmed">33361740</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivera MJ. Dexamethasone and COVID-19: strategies in low-and middle-income countries to tackle steroid-related Strongyloides hyperinfection. American JTrop Med Hyg. 2021;104(5):1611. doi:10.4269/ajtmh.20-1085</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.20-1085</ArticleId><ArticleId IdType="pmc">PMC8103443</ArticleId><ArticleId IdType="pubmed">33720844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu MN, Bhardwaj M, Sah SP. Safety profile of COVID-19 drugs in a real clinical setting. Eur J Clin Pharmacol. 2022;2022:1–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8794611</ArticleId><ArticleId IdType="pubmed">35088108</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupte V, Hegde R, Sawant S, et al. Safety and clinical outcomes of remdesivir in hospitalised COVID-19 patients: a retrospective analysis of active surveillance database. BMC Infect Dis. 2022;22(1):1–8. doi:10.1186/s12879-021-07004-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-021-07004-8</ArticleId><ArticleId IdType="pmc">PMC8724590</ArticleId><ArticleId IdType="pubmed">34983406</ArticleId></ArticleIdList></Reference><Reference><Citation>W-j G, Z-y N, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa2002032</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bangash MN, Patel J, Parekh D. COVID-19 and the liver: little cause for concern. Lancet Gastroenterol Hepatol. 2020;5(6):529–530. doi:10.1016/S2468-1253(20)30084-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-1253(20)30084-4</ArticleId><ArticleId IdType="pmc">PMC7270582</ArticleId><ArticleId IdType="pubmed">32203680</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkas F, Styla C-P, Bechlioulis A, Milionis H, Liberopoulos E. Sinus bradycardia associated with remdesivir treatment in COVID-19: a case report and literature review. J Cardiovasc Develop Dis. 2021;8(2):18. doi:10.3390/jcdd8020018</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd8020018</ArticleId><ArticleId IdType="pmc">PMC7918811</ArticleId><ArticleId IdType="pubmed">33673216</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng L, Xiao K, Ottaviani S, Stebbing J, Wang Y-J. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib. Expert Opin Drug Saf. 2020;19(11):1505–1511. doi:10.1080/14740338.2020.1799975</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14740338.2020.1799975</ArticleId><ArticleId IdType="pubmed">32693646</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen JS, Genovese MC, Takeuchi T, et al. Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment. J Rheumatol. 2019;46(1):7–18. doi:10.3899/jrheum.171361</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.171361</ArticleId><ArticleId IdType="pubmed">30219772</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor PC, Weinblatt ME, Burmester GR, et al. Cardiovascular safety during treatment with baricitinib in rheumatoid arthritis. Arthritis Rheumatol. 2019;71(7):1042–1055. doi:10.1002/art.40841</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40841</ArticleId><ArticleId IdType="pmc">PMC6618316</ArticleId><ArticleId IdType="pubmed">30663869</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F, Kruip M, Van der Meer N, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis. Thromb Res. 2020;191:148–150. doi:10.1016/j.thromres.2020.04.041</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.041</ArticleId><ArticleId IdType="pmc">PMC7192101</ArticleId><ArticleId IdType="pubmed">32381264</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>